RUSSELL PAUL BOWLER

Summary

Publications

  1. ncbi The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes
    Brendan J Carolan
    Department of Medicine, National Jewish Health, 1400 Jackson St, Denver 80206, CO, USA
    Respir Res 15:127. 2014
  2. pmc Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD
    Jen hwa Chu
    Channing Division of Network Medicine, Brigham and Women s Hospital, Boston, MA, USA
    BMC Syst Biol 8:78. 2014
  3. pmc Cigarette smoke decreases airway epithelial FABP5 expression and promotes Pseudomonas aeruginosa infection
    Fabienne Gally
    Pulmonary Division, Department of Medicine, National Jewish Health, Denver, Colorado, United States of America
    PLoS ONE 8:e51784. 2013
  4. ncbi Surfactant protein D as a biomarker for chronic obstructive pulmonary disease
    Russell P Bowler
    Department of Medicine, National Jewish Health, Denver, CO, USA
    COPD 9:651-3. 2012
  5. pmc beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells
    Claire A Gross
    Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, Colorado 80206, USA
    BMC Pulm Med 10:30. 2010
  6. pmc Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease
    Jayaji M Moré
    Department of Medicine, National Jewish Health, Denver, CO, USA
    BMC Pulm Med 10:53. 2010
  7. pmc Alterations in the human lung proteome with lipopolysaccharide
    Russell P Bowler
    Department of Medicine, National Jewish Health, Denver, Colorado, USA
    BMC Pulm Med 9:20. 2009

Collaborators

  • Nichole Reisdorph
  • Edward Abraham
  • Jen hwa Chu
  • Brendan J Carolan
  • Stephen Rennard
  • Craig P Hersh
  • Fabienne Gally
  • Hong Wei Chu
  • Jayaji M Moré
  • Claire A Gross
  • Joseph Loscalzo
  • Debra A Cockayne
  • Nan Laird
  • Rachel L Zemans
  • Grant Hughes
  • Katerina Kechris
  • Benjamin A Raby
  • Edwin K Silverman
  • Alejandro P Comellas
  • Sreekumar G Pillai
  • Paula Belloni
  • Peter J Castaldi
  • Michael H Cho
  • WANDA K O'NEAL
  • Jarrett Morrow
  • John Quackenbush
  • MeiLan Han
  • Dennis R Voelker
  • Christina Schnell
  • Michael G Edwards
  • Lori J Silveira
  • Andrew R Weinberger
  • Edward D Chan
  • Rebecca M Green

Detail Information

Publications7

  1. ncbi The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes
    Brendan J Carolan
    Department of Medicine, National Jewish Health, 1400 Jackson St, Denver 80206, CO, USA
    Respir Res 15:127. 2014
    ..e., nodules). Using a comprehensive biomarker panel, we sought to determine if there was a peripheral blood biomarker signature of emphysema...
  2. pmc Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD
    Jen hwa Chu
    Channing Division of Network Medicine, Brigham and Women s Hospital, Boston, MA, USA
    BMC Syst Biol 8:78. 2014
    ..The investigation of complex disease heterogeneity has been challenging. Here, we introduce a network-based approach, using partial correlations, that analyzes the relationships among multiple disease-related phenotypes...
  3. pmc Cigarette smoke decreases airway epithelial FABP5 expression and promotes Pseudomonas aeruginosa infection
    Fabienne Gally
    Pulmonary Division, Department of Medicine, National Jewish Health, Denver, Colorado, United States of America
    PLoS ONE 8:e51784. 2013
    ..These findings support the development of FABP5/PPAR-γ-targeted therapeutic approach to prevent airway inflammation by restoring antimicrobial immunity during COPD exacerbations...
  4. ncbi Surfactant protein D as a biomarker for chronic obstructive pulmonary disease
    Russell P Bowler
    Department of Medicine, National Jewish Health, Denver, CO, USA
    COPD 9:651-3. 2012
    ..One such candidate is the lung specific protein surfactant protein D (SP-D). In this review, we discuss the evidence supporting SP-D as a COPD biomarker...
  5. pmc beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells
    Claire A Gross
    Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, Colorado 80206, USA
    BMC Pulm Med 10:30. 2010
    ..beta2-agonists are mainstay of COPD and asthma therapy, but whether beta2-agonists directly affect airway epithelial host defense functions is unclear...
  6. pmc Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease
    Jayaji M Moré
    Department of Medicine, National Jewish Health, Denver, CO, USA
    BMC Pulm Med 10:53. 2010
    ..We hypothesized that COPD patients would have reduced bronchoalveolar lavage (BAL) fluid SP-D levels compared to healthy smoking and non-smoking controls...
  7. pmc Alterations in the human lung proteome with lipopolysaccharide
    Russell P Bowler
    Department of Medicine, National Jewish Health, Denver, Colorado, USA
    BMC Pulm Med 9:20. 2009
    ....